Hypothesis

mTOR activity shapes the extracellular vesicle (EV) senescent secretome, determining whether senescent cells are tolerated or eliminated by immune surveillance. When mTOR is active, senescent cells load EVs with miR‑21 and miR‑155 that suppress macrophage phagocytosis, reinforcing a tissue‑level ‘civilization’ state where damaged cells persist. Inhibition of mTOR re‑programs EV cargo toward pro‑inflammatory miR‑146a and DAMPs, enhancing phagocytic clearance and linking the longevity dial to intercellular communication.

Mechanistic Basis

mTORC1 phosphorylates the RNA‑binding protein hnRNPA2B1, promoting its binding to GGAG motifs and loading specific miRNAs into EVs via the ESCRT‑dependent pathway. In senescent cells with constitutive mTORC1, hnRNPA2B1 is hyper‑phosphorylated, biasing EV sorting toward survival‑associated miRNAs. Rapamycin reduces hnRNPA2B1 phosphorylation, shifting the RNA‑binding affinity and altering ESCRT recruitment, thus changing the EV miRNA profile. This provides a direct molecular link between mTOR signaling and the immunomodulatory content of senescent‑derived EVs.

Predictions & Experiments

1. EV miRNA shift – Isolate EVs from irradiated human fibroblasts senescent vs control, treat with rapamycin (100 nM, 24 h). Small‑RNA seq will show decreased miR‑21/155 and increased miR‑146a in rapamycin‑treated senescent EVs (p < 0.01).
2. Functional clearance – Co‑culture macrophages with EVs from each condition; measure phagocytosis of labeled senescent cells. EVs from rapamycin‑treated senescent cells will increase macrophage uptake by >=30% compared with control senescent EVs.
3. In vivo validation – Inject senescent fibroblasts into immunocompetent mice; treat half with rapamycin. Flow cytometry of tissues at day 7 will show a higher proportion of cleared senescent cells (reduced p16^INK4a^+ cells) in rapamycin group, an effect abolished by GW4869 (EV release inhibitor).
4. Phospho‑hnRNPA2B1 rescue – Express a phosphomimetic hnRNPA2B1 mutant (S→D) in senescent cells under rapamycin; EV miRNA profile and macrophage phagocytosis will revert to the rapamycin‑untreated state.

If any of these predictions fail, the hypothesis that mTOR directs EV‑mediated immune clearance of senescent cells is falsified.

Potential Implications

This reframes mTOR inhibition not merely as a cell‑autonomous longevity switch but as a tissue‑level immunomodulatory intervention that re‑educates the senescent secretome to promote ‘civilizational’ turnover. It suggests combining rapamycin with EV‑modulating agents could improve senolytics while preserving beneficial transient senescence in regeneration.